Histone H4 acetylation and the epigenetic reader Brd4 are critical regulators of pluripotency in embryonic stem cells by unknown
RESEARCH ARTICLE Open Access
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Abstract
Background: Pluripotent cells can be differentiated into many different cell types in vitro. Successful differentiation
is guided in large part by epigenetic reprogramming and regulation of critical gene expression patterns. Recent
genome-wide studies have identified the distribution of different histone-post-translational modifications (PTMs)
in various conditions and during cellular differentiation. However, our understanding of the abundance of histone
PTMs and their regulatory mechanisms still remain unknown.
Results: Here, we present a quantitative and comprehensive study of the abundance levels of histone PTMs during
the differentiation of mouse embryonic stem cells (ESCs) using mass spectrometry (MS). We observed dynamic
changes of histone PTMs including increased H3K9 methylation levels in agreement with previously reported
results. More importantly, we found a global decrease of multiply acetylated histone H4 peptides. Brd4 targets
acetylated H4 with a strong affinity to multiply modified H4 acetylation sites. We observed that the protein
levels of Brd4 decreased upon differentiation together with global histone H4 acetylation. Inhibition of Brd4:histone H4
interaction by the BET domain inhibitor (+)-JQ1 in ESCs results in enhanced differentiation to the endodermal lineage,
by disrupting the protein abundance dynamics. Genome-wide ChIP-seq mapping showed that Brd4 and H4
acetylation are co-occupied in the genome, upstream of core pluripotency genes such as Oct4 and Nanog in
ESCs and lineage-specific genes in embryoid bodies (EBs).
Conclusions: Together, our data demonstrate the fundamental role of Brd4 in monitoring cell differentiation
through its interaction with acetylated histone marks and disruption of Brd4 may cause aberrant differentiation.
Keywords: Acetylation, Brd4, Embryonic stem cells, Epigenetics, Histone, Neuronal cells, Post-translational
modifications, Mass spectrometry, ChIP-seq
Background
Embryonic stem cells (ESCs) are self-renewing, pluripo-
tent cells derived from the inner cell mass (ICM) of a
blastocyst [1, 2]. Their ability to expand clonally or dif-
ferentiate into multiple tissues makes them an ideal
model to study cellular development. ESCs have been
used for preclinical drug screening, toxicity testing, cell
therapy in animal models and developing models for
rare diseases, such as Fanconi anemia [3]. Epigenetic
changes in histone and DNA methylation control cell
commitment to a specific lineage [4, 5]. Therefore,
understanding both the genetic and epigenetic mecha-
nisms is important for successful regenerative therapy.
Histone post-translational modifications (PTMs) modu-
late the chromatin landscape by changing overall charge
and by recruiting chromatin modifier enzymes, thereby
facilitating gene expression/repression and DNA repair.
Histone acetylation is associated with gene activation [6].
Loss of H4K16 acetylation at promoters results in de-
creased transcription [7]. While acetylated histones are
found primarily at promoters of actively transcribed genes,
they can also be found throughout the active gene [8].
Histone acetylation has been implicated to be important
for the pluripotent cell state, as some HDAC inhibitors
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have been shown to improve reprogramming efficiency of
induced pluripotent stem cells (iPSCs) or maintain a pluri-
potent stem cell state. For instance, when valproic acid,
an HDAC inhibitor, is added only Oct4 and Sox2 are
needed to reprogram MEFs [9]. Another HDAC in-
hibitor, butyrate, was also shown to improve repro-
gramming efficiency and can also reprogram
myoblasts [10–12]. Since HDAC inhibition facilitates
cellular iPSC reprogramming, histone acetylation may
play an important role in pluripotency.
Histone acetylation is bound by bromodomain-
containing proteins. Especially, acetylated histone H4
is bound by the double bromodomain proteins Brd2,
Brd3, and Brd4, which possess histone chaperone activity,
thus facilitating transcription through nucleosomes [13].
Brds have also been previously shown to play a role in
development. Brd2 mutants are embryonic lethal, with
Brd2 null mouse embryos showing deficient neural tube
formation [14]. Similarly, Brd4 mutants are also embry-
onic lethal, and in vitro experiments show that they are
incapable of maintaining the inner cell mass [15]. Recent
study identified that deletion of Brd4, not Brd2 and Brd3,
disrupts the ESC colony formation in both human and
mouse [16]. Brd4 also regulates ESC self-renewal and the
expression of pluripotency genes [3, 16, 17]. Inhibition of
Brd4 resulted in commitment to the neuroectodermal
lineage [16]. In addition, Brd4 has been found to localize
to and control the expression HOX gene clusters in
HEK293 cells [18]. These double bromodomain con-
taining proteins may have an important role both in
ESC self-renewal and development.
Brd4 recruits the positive transcription elongation factor
b (P-TEFb), which induces the release of the promoter-
proximal paused RNA polymerase II [19]. Brd4 has also
been shown to possess kinase activity and can bind the
carboxy-terminal domain of RNA polymerase II to phos-
phorylate serine 2, which facilitates elongation by recruit-
ing splicing factors [20]. Brd4 has been shown to facilitate
transcription, after being docked by H3K9acS10ph/
H4K16ac [21]. Recent crystal structures showed that while
the second bromodomain of Brd4 binds most di-and tri-
acetylated lysines, the first bromodomain of Brd4 (BD1)
specifically binds di-, tri-, and tetra-acetylated histone H4
[22]. Another study using time-resolved fluorescence
resonance energe transfer (TR-FRET) found that the
strongest binding of BD1 was observed for the tetra-
acetylated H4 peptide and the di-acetylated H4 peptide
with K5 and K8, but weak binding was found for all
mono-acetylated H4 peptide [23].
Even though histone PTMs and their readers are known
to be important during cell differentiation, the changes in
their abundance have not been previously well studied. In
this work we investigated the changes in the quantity of
histone PTMs during ESC differentiation into neuronal
cells using quantitative mass spectrometry (MS) based
proteomics. We found that the cell differentiation involves
consistent rearrangement of global histone PTM abun-
dance. In particular, we observed a reduction of doubly,
triply and quadruply acetylated histone H4, suggesting an
increase in chromatin compaction, and possible gene
expression changes. Interestingly, the expression levels of
Brd4, which recognizes multiply acetylated histone H4 N-
terminal tails, were also reduced during differentiation.
Inhibition of the binding of Brd4 to histone H4 using JQ1,
a specific inhibitor for the Brd family in ESCs, promoted
cell differentiation, while disrupting the coordinated
changes in the quantity of histone PTMs. The genome-
wide investigation using chromatin immunoprecipitation
followed by sequencing (ChIP-Seq) against Brd4 and
histone acetylation at H4 (H4ac) show that Brd4
binds to the pluripotent and lineage specific genes in
embryoid body (EB) from ESCs, suggesting that in-
ability of Brd4 to read H4 acetylation may disrupt
genome-wide acetylation landscapes. Taken together,
our results indicate that monitoring the epigenetic
status through the interaction with acetylated histones
is important for the maintenance of the pluripotency
and the coordinated differentiation of ESCs.
Methods
Cell culture of mouse embryonic stem cells
CCE Nanog-GFP ESCs, a generous gift from Ihor
Lemischka, were cultured in DMEM supplemented
with 15 % FBS, Penicillin-Streptomycin, non-essential
amino acids, 2-mercaptoethanol, sodium pyruvate, and
ESGRO/2i (Life Technologies, Carlsbad, CA, USA), as
adapted from Gaspard et al. [24]. Cells were seeded on
gelatin-coated tissue culture dishes at 2x106 cells per
10 cm dish and passaged every other day. Cells were
grown at 37°C in a humidified 5 % CO2/95 % air incu-
bator. Nanog-GFP was measured by FACS (Wistar In-
stitute Flow Cytometry Facility, Philadelphia, PA,
USA) prior to experiments to verify that >90 % of cells
were pluripotent. No ethics approval was required for
this study.
Retinoic acid differentiation
To differentiate ESCs, we applied the protocol described
earlier [25]. To form embryoid bodies, ESCs were plated
on petri dishes in ESC media containing 10 % FBS and
lacking ESGRO/2i. Cells were incubated on a shaker at
30 rpm for 4 days, changing media on alternate days.
Embryoid bodies were grown for four more days in EB
media containing 1 μM all-trans retinoic acid (Sigma-
Aldrich, St. Louis, MO, USA), changing media also on
alternate days. RA-treated EBs were plated on gelatin-
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coated tissue culture dishes and incubated for a week,
changing media every other day.
Nuclei isolation and histone extraction
Nuclei were isolated and histone proteins were extracted as
described before [26]. Briefly, histones were acid-extracted
from nuclei with 0.2 M H2SO4 for 2 hours and precipitated
with 33 % trichloroacetic acid (TCA) overnight. Samples
were resuspended in 20-30 μl of ddH2O and protein
concentration was calculated using the Bradford assay.
Histone samples were derivatized with propionic anhyd-
ride, digested with trypsin overnight at 37C and re-
propionylated as previously described [26]. Afterwards,
histone peptides were desalted using C18 material.
Reversed phase nano chromatography coupled to mass
spectrometry
Samples were analyzed by using a nanoLC-MS/MS
setup. nanoLC was configured with a 75 μm ID × 17 cm
Reprosil-Pur C18-AQ (3 μm; Dr. Maisch GmbH,
Germany) nano-column using an EASY-nLC nanoHPLC
(Thermo Scientific, Odense, Denmark). The HPLC gra-
dient was 2-35 % solvent B (A = 0.1 % formic acid; B =
95 % MeCN, 0.1 % formic acid) over 30 min and from
34 % to 100 % solvent B in 30 minutes at a flow-rate of
300 nL/min. LC was coupled with an LTQ-Orbitrap
Velos mass spectrometer (Thermo Fisher Scientific, San
Jose, CA). Full scan MS spectrum (m/z 290 − 1400) was
performed in the Orbitrap with a resolution of 60,000
(at 400 m/z) with an AGC target of 1x10e6. The acquisi-
tion method contained both data-dependent and tar-
geted scans. The targeted signals were the histone H3
and H4 peptides in isobaric forms, if any. MS/MS was
performed with collision induced dissociation (CID) with
normalized collision energy of 35, an AGC target of
10e4 and a maximum injection time of 100 ms. MS/MS
data were collected in centroid mode. Precursor ion charge
state screening was enabled and all unassigned charge
states as well as singly charged species were rejected. All
proteomics data has been deposited in the Chorus database
(https://chorusproject.org/pages/dashboard.html#/projects/
all/1013/experiments).
Histone PTM data analysis
The selected modified peptides were quantified using
label-free based extracted ion chromatography. EpiPro-
file was used for the purpose, with a peak extraction
mass tolerance set to 10 ppm [26]. The peptide relative
ratio was calculated by considering the peak area of all
peptides that share the same amino acid sequence as
total peptide abundance, and estimating the percentage
of each individual species by dividing the peak area by
the total peptide abundance.
Western blot analysis
Cells were lysed using TNE buffer (50 mM Tris-HCl,
100mM NaCl, 0.1 mM EDTA). Approximately 10 μg of
cell lysate per sample were run on a 10 % polyacrylamide
gel. The membrane was incubated with the primary anti-
bodies (anti-Brd4: Abcam 128874, anti-Lamin-B1: Abcam
133741, anti-βIII-tubulin: Abcam 18207, anti-Oct4: Abcam
19857, anti-acetyl H4: Millipore 06-866) according to the
manufacturers’ instructions overnight at 4°C. To determine
the sensitivity of detection of the anti-acetyl H4 antibody
(Millipore 06-866), a dot blot was performed. 0.2 μg, 0.4
μg, 0.8 μg, and 1.2 μg of H4 peptides from the Acetyl-
Histone Peptide Pack (Upstate) were spotted onto a nitro-
cellulose membrane. 1.5 μg, 3.0 μg, 6.0 μg, and 12.0 μg of
HPLC purified histone H2B from HeLa and ESCs were
also spotted onto the membrane. The membrane was
incubated with the primary antibody at a 1:2,000 dilution
for 30 minutes at room temperature. The membrane was
incubated with secondary antibody at a 1:10,000 dilution
for 30 minutes at room temperature (Pierce 31463) then
probed with ECL Western Blot Substrate (Pierce).
Gene expression analysis
Cells were homogenized using QIAshredder (Qiagen), and
RNA was isolated using an RNeasy Kit (Qiagen). cDNA
was synthesized using a Superscript III First-Strand Syn-
thesis System (Invitrogen). qPCR was performed using
Power SYBR® Green PCR Master Mix (Applied Biosys-
tems) and the StepOne Real-Time PCR System (Applied
Biosystems) according to manufacturer’s instructions. The
qPCR primers used are listed in Additional file 1: Table S1.
Primers for GAPDH, Oct4, Nanog, Gata4, COL2A1 and
Brd4 were designed using Universal Probe Library Assay
Design Center (Roche), while the rest were published earl-
ier [19, 27, 28]. Relative mRNA abundance to GAPDH
was calculated by DDCt method.
Chromatin Immunoprecipitation-Sequencing (ChIP-Seq)
Approximately 4x107 CCE ESCs and embryoid bodies
were hypotonically lysed in TMSD buffer (40mM Tris
pH7.5, 5mM MgCl2, 250mM sucrose, 1 mM DTT) con-
taining inhibitors (500 μM AEBSF, 5 μM microcystin, 10
mM sodium butyrate). Nuclear pellets were resuspended
in 1 mL micrococcal nuclease digestion buffer (10mM
HEPES pH7.5, 50mM NaCl, 5mM CaCl2, 5mM MgCl2)
containing inhibitors. Micrococcal nuclease (Sigma) was
added to each sample (3 units/1 mL sample) and incu-
bated at 37°C for 30 minutes. The digestion was quenched
by the addition of 20 mM EGTA. Samples were pelleted,
and the resulting supernatant was collected. The pellet
was washed twice with BC50 (40mM Tris pH7.5, 5mM
MgCl2, 50mM NaCl, 5 % glycerol) containing inhibitors,
and the resulting supernatants were pooled with the first
supernatant. Mononucleosomes were immunoprecipitated
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from the supernatant overnight at 4°C using Protein AG
magnetic beads (Pierce) bound to either anti-Brd4 anti-
body (Abcam 128874) or anti-acetyl H4 antibody (Milli-
pore 06-866). The magnetic beads were washed three
times with BC50, then resuspended in ~50uL BC50. The
magnetic beads were treated with RNase A (Roche)
followed by Proteinase K (Denville) according to the man-
ufacturers’ instructions. The samples were then cleaned
up with DNA Clean & Concentrator-5 (Zymogen). The
ChIP library was prepared using the multiplexed ChIP-
Seq sample preparation protocol available on the Univer-
sity of Pennsylvania Functional Genomics Core website
(http://fgc.genomics.upenn.edu/). ChIP libraries were run
on a 2 % agarose gel to verify amplification and size. ChIP
libraries were submitted to SeqMatic (Fremont, CA) for
Illumina HiSeq sequencing. Sequencing data were sent to
BioInfoRX (Madison, WI) for analysis using BxChIPSeq
2.0. Briefly, bowtie [29] was used to align raw sequence
reads to the mouse genome (mm9) with options ‘-v 2-m 1
–best –strata,’ and all of the redundant tags were removed
before downstream analysis. Peak calling was carried out
using HOMER [30] with a default option (FDR = 0.001
and Poisson p-value cutoff = 0.0001) on ChIPed samples
against the matching input samples. Since the two repli-
cates for each ChIP had similar profiles, the data were
combined to make a single peak call. All ChIP-Seq data
were normalized to 10 reads per million mapped reads
(RPM). A specific peak was defined as having an enrich-
ment within a 200 bp region of more than 4-fold between
two cell populations. The remaining peaks were defined as
constitutive. Gene ontology (GO) analysis was performed
by using GREAT [31]. All genomics data have been depos-
ited in the GEO repository (GSE76760).
BET domain inhibition
ESCs were grown in differentiation conditions in ESC
media, and cells were treated with 100nM or 200nM
(+)-JQ1 (Abcam) for 4 days, with media changes on al-
ternate days. DMSO was used as a control.
Results
Global changes of the abundance of histone methylation
and acetylation during ESC differentiation
ESCs were differentiated to embryoid bodies (EBs) by
culturing them in suspension. EBs were further differ-
entiated using all-trans retinoic acid (RA). Microscopy
images were taken at each time point that cells were
collected: ESCs, EBs, RA-treated EBs, and RA-treated
cells plated for 4 and 7 days (Fig. 1). Cells showed
evident morphological changes at each stage, with the
appearance of filamentous projections in the plated
RA-treated cells, consistent with neuronal differenti-
ation using RA. To identify the changes of histone
PTM abundance during ESC differentiation, histones
were isolated from cells collected at each time point
and analyzed by mass spectrometry (MS) using our
Bottom Up MS platform consisting of chemical deriv-
atization and high-resolution MS [32].
The MS analysis provided us with the changes in glo-
bal abundance of histone methylation and acetylation
(Fig. 1b and Additional file 2: Figure S1). The analysis
using principle component analysis (PCA) confirmed
that the histone PTM abundance profiles at ESCs are
distinguishable to those at EBs and RA-treated cells
(Additional file 2: Figure S1A). Statistical analysis using
one-way ANOVA identified the histone PTMs whose
quantities are significantly affected during differentiation.
For instance, H3K9me2 increased (p-value: 5.6e-10) soon
after differentiation into EB, consistent with the increase
of the genome-wide distribution of H3K9me2 upon cell
differentiation [33], while H3K9me1 abundance become
reduced upon differentiation (p-value: 8.8e-13) (Additional
file 2: Figure S1B). Also, H3K4me1 levels were signifi-
cantly reduced upon differentiation among other K4
methylation (17.1 % of the total histone H3 in ESCs be-
came 13.0 % in day 7 differentiated neuronal cells; p-value:
1.6e-5) (Additional file 2: Figure S1), which also well res-
onant to the recent genome-wide survey of H3K4me1 in
various cell types [34]. H3K27me3 drastically reduced
from ESCs to day 7 (from 25.9 % to 7.1 %; p-value: 7.8e-
26), which does not match with the genome-wide survey
where H3K27me3 levels were increased in the normalized
intergenic H3K27me3 signals [34]. The discrepancy with
this study may due to the focal distribution of H3K27me3
in ESCs, which expands upon differentiation [34, 35].
Abundance of H3K36 methylation was also affected espe-
cially in EBs, with 44.4 % H3K36me2 compared to 30.8 %
in ESCs, which may indicate the emergence of mixed cell
populations and non-neuronal lineages consistent with
spontaneous differentiation (Additional file 2: Figure S1B).
The majority of histone acetylation marks become
significantly reduced in their quantity upon RA treatment
including H3K23ac, H4K8ac, H4K12ac and H4K5ac. On
the other hand, H3K14ac and H4K16ac were increased
after differentiation (Additional file 2: Figure S1C), show-
ing dynamic changes in the abundance in histone acetyl-
ation as well as methylation.
Decrease of multiply acetylated lysine on H4 during
differentiation
Unique to our approach is the ability to quantify mul-
tiple histone PTMs. For instance, we observed that
H3K27me3K36me2 was reduced (Fig. 2) while the rela-
tive quantity of H3K36me2 was increasing during the
differentiation (Fig. 1b). Especially, using the intact
peptide GKGGKGLGKGGAKR (histone H4, aa 4-17),
which contains all the histone H4 acetylation sites, we
could also investigate the co-existence of up to four
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histone acetylation marks on lysine residues. We ob-
served unique changes of the combinatorial histone
PTM abundance. Interestingly, multiply acetylated pep-
tides including tetra-acetylated peptide (K5, K8, K12,
K16) were decreased during differentiation. Indeed, ma-
jority of the peptides with multiply-acetylated lysine
were decreased in the differentiated cells compared with
ESCs except for H4K5acK16ac (Fig. 2). This may in part be
due to H4K16ac increasing upon differentiation (Fig. 1b).
In this context, is interesting to note that Brd4 binds to all
multiply acetylated H4 sites except H4K16ac, coupling
histone PTMs to transcriptional elongation [36, 37].
Brd4 is a marker for self-renewal that binds to multiply
acetylated histone proteins
The decreased abundance in multiply acetylated lysine
prompted us to further investigate the abundance of
mono-and multiply acetylated peptides using histone H4
aa 4-17 peptide. We observed that this peptide containing
two, three and four acetylations decreased significantly
during differentiation, while monoacetylated H4 peptides
increased (Fig. 3a). As multiply acetylated histone PTMs
are the potential targets for Brd4, we investigated the
changes of the Brd4 abundance during differentiation.
Western blot analysis of the ESCs, EBs and RA-treated
cells revealed that the pluripotency master regulator
Oct4 decreased as RA differentiation progressed,
while neuronal marker βIII tubulin increased. In line
with down-regulation of Oct4, the protein levels of Brd4
also decreased upon EB formation and further in differen-
tiated cells in the two replicates we investigated (Fig. 3b).
The decreasing levels of histone H4 acetylation observed
in mass spectrometry was not very obviously confirmed in
Western analysis as the antibody was raised to tetra-
acetylated H4. However, a slightly decreasing trend of
acetylated H4 can be seen as ESCs differentiate.
Cells collected at each time-point were also analyzed
by qRT-PCR for expression of Oct4 (Pou5f1), Brd2 and
Brd4 (Fig. 3c). EBs were grown for 4 days in suspension;
RA after 4 days grown in suspension with RA. RA 4d
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Fig. 1 Cell morphology and dynamic changes in abundance of histone PTMs. a Retinoic acid differentiation of ESCs results in neuronal cells.
From top to bottom, CCE ESCs were grown in suspension for 4 days in the absence of LIF/2i to form embryoid bodies. The embryoid bodies
were treated with 1 μM all-trans retinoic acid for 4 days. Cells were plated on gelatin-coated plates and grown for 4 days and 7 days. Red scale
bar represents 100 μm. b Relative abundance of histone PTMs during cell differentiation. Heatmap of all single histone modifications from histone
H3 and H4, calculated by summing the relative abundance of all peptides carrying each given PTM. A and B represent the two biological
replicates for each analyzed time point. The represented value was obtained by averaging the three technical replicates and performing
z-score normalization for the rows































































































































Fig. 2 Histone peptide regulation during differentiation. Heatmap of all quantified peptides using nLC-MS from histone H3 and H4. A and
B represent the two biological replicates for each analyzed time point. The represented value was obtained by averaging the three technical
replicates and performing z-score normalization for the rows.
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and RA 7d were grown on gelatin coated plates (Fig. 3c).
Oct4 levels were maintained in EB, indicating lingering
presence of Oct4 transcripts. On the other hand, Oct4
decreased rapidly upon differentiation in the presence of
RA which is a strong differentiation agent. Importantly,
Brd4 levels decreased upon RA differentiation, syn-
chronous with Oct4 expression, further indicating that
their expressions are linked each other. We also investi-
gated the expression of another related BET domain
protein, Brd2. We found that in general, the expression
of Brd2 also somewhat mirrored the overall Brd4 and
Oct4 expression trend, to the extent of showing a spike
in the EB stage, similar to Oct4. This may explain in-
crease of some acetylation marks at EB stage. However,
the changes of its levels in the differentiated cells com-
pared with ESCs are not significant. Besides, previous
study found that Brd2 does not disrupt the self-renewing
characteristics of ESCs [16]. Taken together, all this data
suggest that histone acetylation and Brd4 are most likely
the major epigenetic determinants of ESC pluripotency.
Effect of BET domain inhibition on the epigenome and
cellular pluripotency
In order to confirm the role of Brd4 during differenti-
ation, ESCs were treated with either 100 nM or 200 nM
of the BET domain inhibitor (+)-JQ1 for 4 days (Fig. 4a).
Since the ESCs were engineered to express Nanog-GFP,
we assessed pluripotency by FACS as Nanog is only
expressed in pluripotent cells. About 91 % of the ESCs
were Nanog-GFP positive, while it was about the same
in DMSO (86 %) As expected, (+)-JQ1-treated ESCs
showed a decrease in Nanog-GFP: about 68 % expressing
Nanog-GFP following 100 mM (+)-JQ1 treatment and 61 %
following with 200 mM (+)-JQ1 treatment (Fig. 4a).
For further analysis of gene expression subsequent to
BET inhibition, the expression level of markers for endo-
derm, mesoderm and neuroectoderm in the following
conditions were analyzed: ESC (Day 0), DMSO control
(-RA-JQ1), 1 μM RA treatment for 6 days (+RA-JQ1), 2
μM JQ1 treatment for 6 days (-RA + JQ1) and RA for 3
days followed by JQ1 for 3 days (+RA to JQ1). All differ-
entiation conditions were devoid of LIF. In order to
compare the relative mRNA expressions ranging from
0.00003946 to 1, the data was normalized using z-score
and was represented as relative fold over DMSO control
(-RA-JQ1) (Fig. 4b). As expected, all the three treatment
conditions downregulated expression of pluripotency
genes, Oct4 and Nanog. Brachyury, a mesodermal
marker seems to be either unchanged or very low
compared to DMSO control. Surprisingly, there was
induction of both endoderm and neurectoderm markers
with all treatment regimens. However late endoderm
marker specific for hepatocytes, Alb (albumin) was not
detected. Average expression of all endodermal markers
was similar to that of neurectodermal markers (3.22 vs
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Fig. 3 Regulation of histone acetylation and Brd4. a Analysis of the acetylated state of the peptide of histone H4 aa 4-17. The singly acetylated
form increases during differentiation, while the hyperacetylated states decrease. Above the bars in red the ANOVA p-value (one tail test) among
the different conditions is displayed. b Western blotting of Brd4, Oct4 βIII-tubulin and Lamin, this last one used as control. Brd4 decreases during
differentiation, and so Oct4. On the bottom, antibody recognizing acetylated histone H4. c qRT-PCR of Oct4 (Pou5f1, in black), Brd2 (in red) and
Brd4 (in green) across the five time points of the differentiation process. Actin was used as the reference gene
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"+RA -JQ1 "-RA +JQ1 "+RA to JQ1
Pluripotency mOct4 -4.01 -0.33 -0.90
Pluripotency mNanog -4.15 0.59 -1.38
Mesendoderm mBrachyury 0.90 -10.01 0.40
Endoderm mFoxA2 5.34 1.79 5.21
Endoderm mCXCR4 3.49 -1.34 1.65
Endoderm mSox17 5.30 2.68 5.82
Endoderm mGsc -0.47 0.05 0.84
Endoderm mGata4 2.42 3.74 5.05
Endoderm mAlb N/D N/D N/D
Mesoderm mCol2A1 3.30 2.73 3.01
Neuroectoderm mSox1 1.29 1.55 0.84
Neuroectoderm mNcadherin 5.85 3.57 4.77
Neuroectoderm mPax6 2.61 0.93 1.38
Neuroectoderm mCycD1 1.94 -1.06 0.58
Neuroectoderm mZFp521 3.83 2.26 3.01
Neuroectoderm mIsl1 2.61 2.33 4.01
Neuroectoderm mMsx1 7.63 3.02 4.71
Neuroectoderm mSox3 1.58 0.36 0.63
Target mBrd4 -1.11 -0.99 -0.77
Endoderm average 3.22 1.38 3.71
Neuroectoderm average 3.42 1.62 2.49
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Fig. 4 (See legend on next page.)
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confirmed that JQ1 promoted differentiation comparable
to RA. The potency of RA and JQ1 is validated by inhib-
ition of Brd4 expression in all treatment conditions.
However, unlike earlier reported, we did not find JQ1
augmenting the neurectodermal induction by RA when
treated with in succession (+RA to JQ1) [28].
In addition, histones were analyzed and compared to
DMSO-treated ESCs. Histone modifications also were
found to change in their relative abundance upon
(+)-JQ1 treatment (Fig. 4c, d, e and Additional file 3:
Figure S2). As we predict JQ1 to promote differentiation,
we noted that both concentrations of (+)-JQ1 provided
very comparable effects on the fold changes of histone
PTMs as compared to ESCs control (Fig. 4d, e). BRD4
was reported to bind to enhancers with H3K4me1 [38]
and in this study, JQ1 decreased H3K4me1 (Fig. 4c). The
vast majority of acetylated marks were found to be regu-
lated (Fig. 4c and Additional file 3: Figure S2). Acetylation
such as H4K16ac that are decreased in differentiation,
were also decreased upon JQ1 treatment, indicating that
JQ1 treatment had no effect on this mark. This is in agree-
ment with H4K16ac not being the binding partner of
BRD4 [39]. Similarly, tetra-acetylated peptide (K5, K8,
K12 and K16) increased upon the JQ1 treatment, suggest-
ing that decrease of the tetra-acetylation is not a require-
ment for cell differentiation. On the other hand, H3K79ac
and K9ac were increased on BRD4 inhibition. Moreover,
di-acetylated peptide (K5 and K16) and tri-acetylated pep-
tide (K5, K12 and K16) were significantly reduced. These
show that JQ1 facilitates cell differentiation, but the epi-
genetic landscapes it changes are rather broad and should
only be interpreted in a locus-specific manner. Collect-
ively, our data suggest that differentiation of ESCs is
tightly linked to failure of Brd4 binding to chromatin,
which alters the global epigenome.
Re-distribution of Brd4 biding site during differentiation
To understand the role of Brd4 in pluripotency, we per-
formed ChIP-Seq against Brd4 and the highly acetylated
state of histone H4. We first confirmed the specificity of
both the Brd4 (Abcam 128874) and acetyl-H4 antibodies
(Millipore 06-866). The Brd4 antibody normally detected
a 250 kDa protein (Additional file 4: Figure S3). For de-
tecting acetyl-H4, we dot blotted 0.2 μg-1.6 μg of H4
peptides (individual monoacetylated peptides and a tet-
raacetylated peptide), as well as nuclear extract from
HeLa and ESC cells. Hybridization of anti-acetyl H4 to
H4 (residues 1-20) peptides (K5ac, K8ac, K12ac and
K16ac) revealed that among the singly acetylated H4
peptides, the antibody slightly recognizes H4 acetylated
at K5, strongly recognizes H4 acetylated at K8 and at
K12, but does not recognize H4 acetylated at K16
(Additional file 4: Figure S3). More importantly, the
antibody also strongly recognizes the tetra-acetylated
H4 peptide, acetylated at all four lysine residues (K5,
K8, K12 and K16). It does not recognize the unmodi-
fied H4 peptide, which was the biggest concern for
non-specific binding. Due to the similar nature of his-
tone H2B tails, HPLC-purified H2B from HeLa and
ESCs were tested as well. The anti-acetyl H4 antibody
has some slight cross-reactivity with H2B, an unfortu-
nate, but unavoidable small issue.
To understand the role of Brd4, we further investigated
genomic distribution of Brd4 in ESCs and EBs. Applying
the Homer peak calling algorithm, we identified 2,754
ESC specific, 567 EB specific and 11,128 peaks constitu-
tive to both cell types (Fig 5a). Gene ontology (GO) ana-
lysis using GREAT found that the enriched terms for the
EB specific peaks include “hypothalamus development”
and “cerebellar Purkinje cell differentiation”, suggesting
that Brd4 gained binding close to the genes related with
neuronal development in EBs (Fig 5b). On the other hand,
the enriched terms for the ESC specific peaks include
“head morphogenesis” and “regulation of osteoclast differ-
entiation”, suggesting that loss of Brd4 for the develop-
mental genes other than neuronal development in EBs
(Fig. 5c). The constitutive peaks are enriched for the terms
such as “regulation of intrinsic apoptotic signaling
pathway”, “blastocyst formation”, and “histone H4-K5
acetylation” (Additional file 5: Figure S4).
(See figure on previous page.)
Fig. 4 Analysis of key regulatory proteins and histone PTMs during JQ1 cell treatment. a (+)-JQ1 treatment of ESCs results in a decrease in
Nanog-GFP as measured by FACS. b In triplicate experiments, ESCs were initiated into differentiation in medium lacking LIF. Matched cultures
comprising DMSO control (-RA-JQ1), RA treatment for 6 days (+RA-JQ1), JQ1 treatment for 6 days (-RA + JQ1) and RA for 3 days followed by JQ1
for 3 days were maintained and for 6 days with media changes on alternate days. On harvest, mRNA abundance was analyzed by qPCR using a
panel of primers (Additional file 1: Table S1). The DDCt data was represented as relative fold over DMSO control (-RA-JQ1). Expression of pluripotency
markers, Oct4 and Nanog decreases upon RA and (+)-JQ1 treatment as compared to DMSO control without drug, while expression of germ
layer markers increased. The trends of differentiation by inhibition of BET domain by these two treatments and a combination thereof
are shown as averages (bottom cells) of multiple markers, respectively for endoderm and neurectoderm. c Most significant histone PTM
changes during inhibitor treatment. d Representation of all histone PTMs by plotting their log2 fold change between untreated cells and
treated with 100 nM (left) or 200 nM (right) of JQ1 inhibitor. Significant changes were considered when the–test p-value (homoscedastic,
two tails) was <0.05, equivalent to >4.32 when transformed into–log2. Color code represents different histone modification types. e Representation of
all histone peptide regulations in cells untreated vs treated with JQ1. The two different doses were marked with black and red dots. The figure displays
a tight correlation of histone peptide regulation between the two treatments











Fig. 5 Redistribution of Brd4 binding sites during differentiation. a ChIP occupancy for ESC (red) and EB (green) specific Brd4 peaks. Read per
million (RPM) was calculated for the Brd4 occupancy in ESC and EBs (b) GO for EB specific peaks. Terms related with neuronal differentiation are
enriched (c) GO analysis for the ESC specific peaks
a b
c d
Fig. 6 Genes associated with H4ac and Brd4 binding. Brd4 and H4ac occupancies in ESCs and EBs are shown. a) Constitutive Brd4 peaks near
Pou5f1 (b) EB specific increase in Brd4 occupancy at Leafy1 promoter (c) EB-specific Brd4 peaks at Wnt3 promoter (d) ESC specific Brd4 peaks at
Il17f promoter
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Oct4 (Pou5f1), a marker for pluripotency showed con-
stitutive Brd4 peaks between ESCs and EBs (Fig 6a). The
promoter region of left-right determination factor 1
(Lefty1), which is important for axis development [40],
also have the constitutive peaks, but its Brd4 levels are
stronger in EBs (Fig 6b). Wnt3, important factor for neur-
onal development [41] also gained a Brd4 peak at its pro-
moter region (Fig 6c). IL-17F, an important factor for T
cells, lost the Brd4 peak in ESCs, These well represent that
EBs have mixed population of stem cells and already com-
mitted cells and Brd4 reflects the characteristics of cells.
Cell-type specific Brd4 peaks match well with the enrich-
ment of H4ac (Fig, 6 and Additional file 6: Figure S5),
showing the high affinity of Brd4 with H4ac. Brd4 over-
lapped with more than 20 % of pluripotent factors (Oct4,
Sox2, and Nanog) and more than 30 % of c-Myc and n-
Myc binding sites within 1Kbps [42]. However, the overlap
with an insulator CTCF is only 6 percent. These show that
Brd4 is involved in transcriptional mechanism of diverse
TFs, but not with insulators (Additional file 7: Table S2).
Discussion
Brd4 among other BET domain family members
uniquely characterizes ESC maintenance [3, 16, 17]. We
investigated the role of Brd4 using proteomic as well as
genomic approaches during differentiation and sought
functional validation by treating with the Brd4 inhibitor,
JQ1. Our proteomic approaches revealed the changes in
the abundance of histone PTMs, which were dynamic-
ally regulated during the ESC differentiation. For in-
stance H3K4me1, a mark associated with enhancers for
active transcription [43] decreased during differentiation
in this study and could well be used to localize genes
that were turned on in the RA-directed ESC differenti-
ation model by ChIP-Seq. On the other hand, this study
confirms earlier reports of depletion of H3K27me3 dur-
ing differentiation [44]. Besides these and other signifi-
cant changes in many acetylated sites, we quantified
histone PTMs such as H3K18me1 and H3K23me1 that
have not been well studied previously. The current data
embodies evidence for unknown roles for these PTM
marks during differentiation.
Changes in global acetylation levels were marked during
differentiation with RA and JQ1. One example is global re-
duction of H3K9acK14ac. This agrees with the previous
work indicating that H3K9ac and H3K14ac co-localize
with bivalent domains (H3K4me3 and H3K27me3) in
ESCs [45]. Therefore, the decrease of H3K9acK14ac may
be linked to the loss of bivalent domains upon differenti-
ation. Moreover, H3K9me2K14ac and H3K9me3K14ac are
significantly increased in differentiated cells compared to
ESCs. This is not surprising since H3K9me2 and
H3K9me3 have been shown to be a barrier to pluripotency
of reprogrammed induced pluripotent stem cells [46, 47].
Majority, except for H3K14ac and H4K16ac, of the acet-
ylated peptides were decreased in differentiation, indicat-
ing that acetylation marks may be differentially regulated
during differentiation. Interestingly, tetra-acetylated pep-
tides in H4 (K5, K8, K12 and K16) were reduced in their
abundance during differentiation. These multiply acety-
lated H4 peptides are the major target for Brd4. As noted
earlier, H4K16ac, which increased in its abundance during
differentiation is not the binding partner of Brd4 although
Brd4 binds to many other kinds of histone acetylation
[39].
Brd4 is the double bromodomain protein that binds
hyperacetylated histone H4 and promotes passage of
elongating RNA polymerase II through activating tran-
scribed genes. There was a correlation between decrease
in Brd4 abundance and histone H4 hypoacetylation
(Fig. 3a and c) in differentiating ESCs. This was further
mirrored in Brd4 inhibition studies where the BET do-
main inhibitor (+)-JQ1 counteracts and inhibits Brd4
binding to target chromatin sites in ESCs and caused the
ESCs to differentiate as determined by decreased Nanog-
GFP expression, and by qRT-PCR for pluripotency and
differentiation. It is conceivable that Brd4 activates these
genes by binding to acetylated histone H4.
Western blotting confirmed that the pluripotency fac-
tor Oct4 decreased upon differentiation, while the
neuron-specific βIII tubulin protein increased. Concomi-
tantly, Brd4 levels decreased immediately upon EB for-
mation and further with RA induced differentiation.
Moreover, qRT-PCR analysis performed on Oct4, Brd2,
and Brd4 showed that while both Oct4 and Brd4 expres-
sion decreased upon differentiation, while Brd2 expres-
sion did not show the same immediate trend. This
suggests that Brd2 and Brd4 have potential different
functions in pluripotency and differentiation. In agree-
ment with these results, a study recently showed that
Brd4 depletion impairs ESC colony formation while
Brd2 depletion has no such effect [3]. The decrease of
Brd4 with differentiation led to the next question of
whether inhibition of Brd4 could also induce cellular
differentiation.
Inhibition of Brd4 by (+)-JQ1 treatment of ESCs was as-
sociated with corresponding down-regulation of the pluri-
potency genes, Nanog and Oct4, presumably through
inhibited Brd4. These observations are consistent with pre-
vious work demonstrating Brd4 regulation of Nanog and
Oct4 expression [3, 16]. The induction of neurectodermal
lineage was evidenced by the concomitant increase in the
expression of panel of markers (Sox1, NCadherin, Pax6,
CycD1, ZFp521, Isl1, Msx1 and Sox3). Besides, RA also
induced endoderm and this effect is well-documented. RA
is a morphogen that has been used in in vitro pancreatic
differentiation protocols for inducing early pancreatic
markers [27, 48]. Elsewhere, studies have reported the
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induction of neurectoderm over endoderm [3, 19]. Simi-
larly, RA has been shown to potentiate mesoderm in ES
cells in the presence of other morphogens such as BMP
[49]. However, induction of these germ layers by JQ1-
effected Brd4 inhibition resulted in an increase in H3K9
methylation, which is known to be associated with differ-
entiation [50]. Further, Brd4 peaks overlapped with H4ac
enrichment in our ChIP-Seq analysis. These experiments
indicate that Brd4, histone H4 acetylation and active tran-
scription presumably of master developmental genes (i.e.
Oct4) are linked, and the genome-wide localization of Brd4
confirms its involvement in pluripotency.
Contrary to the global decrease of H4 tetra-acetylation
upon the JQ1 treatment, we identified global increase of
acetylation histone forms. This indicates that the epigen-
etic landscape becomes disrupted after JQ1 treatment.
The genome-wide re-distribution of Brd4 strongly indi-
cates that Brd4 maintains self-renewal as well as play a
role during differentiation in concert with acetylated
histone PTMs. The loss of the Brd4 function by JQ1
may prevent cells from monitoring the levels of acety-
lated histones. The loss of monitoring function may
responsible for the increase of tetra-acetylation upon
JQ1 treatment.
Conclusions
Collectively, our data demonstrate that Brd4 plays a fun-
damental role in regulating cell differentiation with its
binding to acetylated histones. Specifically our inhibitor
treatment study proves that disruption of Brd4 inter-
action to acetylated histone marks may cause aberrant
differentiation.
Availability of supporting data
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Additional file 1: Table S1. Primer sequences for qPCR analysis w/o RA
and JQ1 treatment (from Fig. 4B) (XLSX 9 kb)
Additional file 2: Figure S1. (A) Principal component analysis (PCA) of
the ten samples analyzed. The yellow oval marks the initial time point, i.e.
ESCs, while the blue oval represents the final stage of cell differentiation.
(B) Statistical changes for the major methylated sites of histone H3 across
all stages of differentiation. The p-value, represented in parenthesis for
each PTM, was calculated by performing ANOVA (one tail). (C) Most
significant changes of histone H3 and H4 acetylations. The–Log10 of the
ANOVA p-value was represented in boxes above the bar plot (significant
if >1.30, equivalent to the–Log10 of <0.05). (PPTX 96 kb)
Additional file 3: Figure S2. Histone peptide regulation during JQ1
treatment. Heatmap of all quantified peptides using nLC-MS from histone
H3 and H4 in ESCs and ESCs treated with JQ1 inhibitor. (PPTX 461 kb)
Additional file 4: Figure S3. Validation of antibody against histone H4
acetylation and ChIP-Seq of key chromatin binding proteins. Dot blot
testing the specificity of anti-H4 acetyl antibody. Specific amounts of
various H4 peptides and histone H2B were dotted onto the membrane.
Antibody strongly recognizes H4 peptide singly acetylated at K8 or K12,
and tetra-acetylated H4 (K5, K8, K12, K16). (PPTX 183 kb)
Additional file 5: Figure S4. GO analysis for the peak constitutive for
both ESCs and EBs. (PPTX 711 kb)
Additional file 6: Figure S5. Heatmap for ESC and EB specific Brd4
binding sites. Brd4 binding well matches with the enrichment for H4ac.
(PPTX 526 kb)
Additional file 7: Table S2. The overlapping peaks of Brd4 with TFs in
ESCs within 1Kbps. (XLSX 10 kb)
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